SRRK Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.